Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors

• Status: Completed
• Trial end date: 2006-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Open, non-randomised, radiolabelled, single centre study with a total of six patients with solid metastatic tumors to determine the rates and routes of elimination of 14C-AZD2171 and its metabolites.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Cediranib

Criteria

Inclusion Criteria:

• histologically confirmed metastatic tumor which is refractory to standard therapies

• life expectancy is 12 weeks or longer

• WHO performance status is 0-12

Exclusion Criteria:

• radiotherapy and chemotherapy within 4 weeks before the start of the study treatment

• patients with a history of poorly controlled hypertension

• history or evidence of any medical condition that might affect gastrointestinal function

• patients that have participated in a radiolabelled study in the last 5 years